Discover Top Posts Tagged with #cyramza

Top Pharma News of the Week – April 23rd

All The Most Important Pharmaceutical News Stories Of The Week – April 2018 – Week #4 Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease April 16, 2018

Boehringer Ingelheim and Eli Lilly and Company have announced an academic collaboration with the University of Oxford to…

View On WordPress

#Aimovig™#AMGen #Biogen #Boehringer Ingelheim #CYRAMZA #Eli Lilly and Company #Ionis #Jardiance #Merck #Novartis #OCREVUS #Pear Therapeutics #relebactam #Roche #Sandoz #Shire plc #siponimod #Takeda #University of Oxford

Lilly's Cyramza succeeds in late-stage liver cancer tri... - https://wp.me/p8XyML-nrK - #Cancer, #Cyramza, #Latestage, #Lillys, #Liver, #Succeeds, #Tri

#cancer #Cyramza #latestage #Lillys #liver #succeeds #tri

Top Pharma News of the Week

FDA Accepts Supplemental Biologics License Application for Prolia® (Denosumab) in Glucocorticoid-Induced Osteoporosis

October 9, 2017

Amgen has announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA,…

View On WordPress

#AbbVie #Alecensa #AMGen #apalutamide #CYRAMZA #Eli Lilly and Company #Janssen #lorlatinib #LYRICA® CR #Pfizer #Prolia #Roche #Turnstone Biologics #Verzenio #ZYTIGA

Lilly's Cyramza Phase III Disappointing, but Has Silver Lining

Lilly’s Cyramza Phase III Disappointing, but Has Silver Lining

Eli Lilly and Co’s recently approved stomach cancer drug Cyramza failed to prolong the lives of patients with advanced liver cancer in a late-stage trial, the drugmaker said on Wednesday.

Patients enrolled in the trial previously had failed to benefit from standard chemotherapy for liver cancer.

(more…)

View On WordPress

#Breast Cancer #Colorectal Cancer #CYRAMZA #Eli Lilly #Lung Cancer

Lilly's CYRAMZA Announces Positive Phase III Results

Lilly’s CYRAMZA Announces Positive Phase III Results

Eli Lilly and Company (NYSE: LLY) today announced detailed results from REVEL, a global Phase III study of CYRAMZA™ (ramucirumab) in combination with chemotherapy in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA8006). REVEL is…

View On WordPress

#CYRAMZA #Eli Lilly #Lung Cancer #Phase III

#cyramza

Trending Tags

Recently Viewed Tags

#cyramza